Table 1.
Outcomes of transplant in the largest studies to date.
| Author (Reference) | Year1 | Number of Patients | Unrelated | Related | Conditioning Regimen (number of patients per regimen) | GvHD prophylaxis | Number of patients with aGVHD <2 | Number of patients with aGVHD>2 | cGVHD | Overall Survival Causes of death2 | DFS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Seger et al. (65) | 2002 | 27 | 2 | 25 | MA(17): Bu/Cy MA(1):Bu/Mel/Alemtuzumab MA(1):Bu/Cy/ATG MA(1): Bu/Cy/TNI MA(1):Bu/Cy/TT/ATG MA(1):Bu/Flu/ATG NMA(2):Bu/Flu ATG NMA(1): Flu/Cy/ATG NMA(1): Flu/TBI |
Cyclosporine (27) Methotrexate (13) Prednisone(4) |
3 | 4 | 3 | 23/27 Multiorgan failure, Pneumonia and GVHD, Pneumonia, Nonengraftment with aspergillus and VOD, |
22/27 |
| Horwitz et al. (69) | 2001 | 10 | 0 | 10 | NMA: Cy/Flu with ATG and Donor lymphocyte Infusions | Cyclosporine | 3 | 1 | 2 | 7/10 Graft failure with retransplant, Pneumococcal pneumonia, GVHD with fungal infection |
6/10 |
| Soncini et al. (66) | 2009 | 20 | 10 | 10 | MA(16):Bu/Cy, +/− Alemtuzumab^ MA(1):Bu/Mel/Campath1-G NMA(2):Flu/Mel/Alemtuzumab NMA(1)Bu/Flu/Alemtuzumab |
Cyclosporine | 5 | 0 | 3 | 18/20 Fungal infection |
18/20 |
| Schuetz et al. (62) | 2009 | 12 | 9 | 3 | MA/MSD: Bu/Cy MA/MUD(6): Bu/Cy/Flu + Alemtuzumab or ATG MA/MUD(2): Flu/Mel/RIT* ?/MUD(1): Flu/TBI |
Not reported | 5 | 0 | 2 | 9/12 Chronic GvHD, ARDS, BK virus |
7/12 |
| Gungor et al. (71) | 2010 | 24 | 9 | 15 | NMA: Dose adjusted IV Bu, Flu, Alemtuzumab | Mycophenolate | 9 | 0 | 0 | 23/24 Pneumonia |
22/24 |
| Kang et al. (72) | 2011 | 11 | 9 | 2 | NMA: IV Bu, Alemtuzumab +/− 300cGy radiation^ | Rapamycin | 2 | 0 | 0 | 10/11 Refusal to continue dialysis |
8/11 |
GvHD-Graft versus Host Disease, a- acute, c-chronic, DFS-Disease Free Survival, MA-Myeloablative, NMA-Nonmyeloablative, Bu-Busulfan, Cy-Cyclophosphamide, Mel-Melphalan, ATG-Antithymocyte Globulin, TNI-Total Nodal Irradiation, TT-Thiotepa, Flu-Fludarabine, RIT-Radioimmunotherapy, VOD-Venoocclusive disease, MSD-Matched Sibling Donor, MUD: Matched Unrelated Donor, ARDS-Acute Respiratory Distress Syndrome,
1
-Year published,
2
-Each cause listed per patient
^
-for unrelated donor recipients,
*
-Radionimmunotherapy=anti-CD66 Yttrium-90 labeled antibody (17Gy)